Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 16/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 15/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14564551 | 0.89 | ADORA2B (1.00) | ADORA2BADORA2AADORA3ADORA1 | |
| SCHEMBL7235224 | 0.86 | ADORA2B (1.00) | ADORA2BADORA2AADORA3ADORA1 | |
| Aminomethylamide SCHEMBL9596537 | 0.82 | ADORA2A (0.89) | ADORA2BADORA2AADORA3ADORA1 | |
| SCHEMBL10728902 | 0.79 | ADORA2A (0.65) | ADORA2BADORA2AADORA3ADORA1 | |
| SCHEMBL10723870 | 0.79 | ADORA2A (0.81) | ADORA2BADORA2AADORA3ADORA1 | |
| SCHEMBL7228457 | 0.79 | ADORA2B (1.00) | ADORA2BADORA2AADORA3ADORA1 | |
| SCHEMBL10750202 | 0.78 | ADORA2A (0.73) | ADORA2BADORA2AADORA3ADORA1 | |
| SCHEMBL10849351 | 0.78 | ADORA2A (0.80) | ADORA2BADORA2AADORA3ADORA1 | |
| SCHEMBL10723882 | 0.78 | ADORA2A (0.80) | ADORA2BADORA2AADORA3ADORA1 | |
| SCHEMBL10852013 | 0.78 | ADORA2B (0.72) | ADORA2BADORA2AADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11857600-B2 | GPCR heteromer inhibitors and uses thereof | GPCR THERAPEUTICS, INC. (KR) | 2024-01-02 | — | — | US | disclosed |
| US-11376269-B2 | Pharmaceutical compositions for the treatment of chemoresistant acute myeloid leukemia (AML) | INSERM (FR) | 2022-07-05 | — | — | US | disclosed |
| EP-3744348-B1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHEMORESISTANT ACUTE MYELOID LEUKEMIA (AML) | INST NAT SANTE RECH MED (FR) | 2022-03-23 | — | — | EP | disclosed |